8-K: CRISPR Therapeutics Enters Collaboration and License Agreement with Sirius Therapeutics, Inc.

CRISPR Therapeutics AG will collaborate with Sirius Therapeutics to develop siRNA technology targeting Factor XI, issuing $70 million in common shares and $25 million in cash upfront.

Summary

• CRISPR Therapeutics AG has entered into a Collaboration, Option, and License Agreement with Sirius Therapeutics.
• The collaboration focuses on research, development, manufacture, and commercialization of products using Sirius siRNA technology to target Factor XI.
• Sirius grants CRISPR Therapeutics options to exclusively license siRNA technology for up to two licensed targets.
• CRISPR Therapeutics will issue approximately $70.0 million of its common shares and make a $25.0 million cash payment to Sirius-CY as upfront consideration.
• The company will issue 1,842,105 common shares at an issue price of $38.00 per share.
• A joint steering committee (JSC) will be established to oversee activities under the agreement, with equal representation from both companies.
• For collaboration products, CRISPR Therapeutics and Sirius will equally share all development and commercialization costs.
• CRISPR Therapeutics will pay Sirius future development and regulatory milestones of up to $87.5 million for collaboration products.
• CRISPR Therapeutics has options to exclusively license Sirius siRNA technology to target up to two licensed targets, with a $10.0 million payment per option.
• CRISPR Therapeutics will pay Sirius up to $300.0 million in development, regulatory, and sales milestones for each licensed target.
• Tiered royalty payments in the mid-single digits to low double digits range will be paid on future sales of licensed products.

Sentiment

Score: 7

Explanation: The document presents a positive collaboration agreement with potential for future growth, but also includes risks associated with clinical trials and financial obligations.

Positives

• The collaboration expands CRISPR Therapeutics' portfolio into siRNA-based therapeutics.
• The agreement provides CRISPR Therapeutics with exclusive options to license Sirius' siRNA technology for multiple targets.
• The collaboration allows for shared development and commercialization costs for collaboration products.
• SRSD107, a next-generation siRNA, has shown promising Phase 1 clinical trial results with sustained reductions in FXI levels.

Negatives

• The company is issuing a significant number of common shares ($70 million) which may dilute existing shareholders.
• The company is paying a significant amount of cash upfront ($25 million).
• The company is subject to potential milestone payments and royalties, which could impact future profitability.
• The success of the collaboration and licensed products is dependent on future clinical trial results and regulatory approvals.

Risks

• The development of collaboration and licensed products may face regulatory hurdles and clinical trial failures.
• The commercialization of products may be impacted by competition and market acceptance.
• The company's financial performance may be affected by the milestone payments and royalties due to Sirius.
• The company may face challenges in integrating Sirius' siRNA technology into its existing platform.

Future Outlook

The collaboration aims to develop and commercialize novel siRNA-based therapeutics targeting Factor XI, with potential applications in various thrombotic conditions. Phase 2 clinical trials for SRSD107 are being initiated to evaluate its safety and efficacy in preventing venous thromboembolism.

Industry Context

The collaboration reflects a growing interest in siRNA-based therapeutics as a promising approach for targeting specific disease pathways. Factor XI inhibition is gaining attention as a potential strategy for reducing thrombotic events with a lower risk of bleeding compared to traditional anticoagulants.

Comparison to Industry Standards

• Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with several approved products and a broad pipeline.
• Dicerna Pharmaceuticals (acquired by Novo Nordisk) also focuses on RNAi therapeutics, targeting various diseases.
• Arrowhead Pharmaceuticals is developing RNAi therapies for liver diseases and other indications.
• These companies, like CRISPR Therapeutics in this collaboration, are leveraging RNAi technology to develop targeted therapies with potentially improved safety and efficacy profiles.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new common shares.
• Employees may benefit from new opportunities in research and development.
• Patients may benefit from new therapeutic options for thrombotic conditions.
• Sirius Therapeutics will receive upfront payments, milestone payments, and royalties.
• Suppliers may benefit from increased demand for research and manufacturing services.

Next Steps

• Establishment of a joint steering committee (JSC) to oversee activities under the agreement.
• Initiation of a Phase 2 clinical trial of SRSD107 to evaluate its safety and efficacy in preventing venous thromboembolism.
• Potential exercise of options to exclusively license Sirius siRNA technology for up to two licensed targets.
• Continued research, development, manufacture, and commercialization of collaboration products and licensed products.

Key Dates

Keywords

CRISPR Therapeutics, Sirius Therapeutics, siRNA, Factor XI, Collaboration, License Agreement, Milestone Payments, Royalties, SRSD107, Gene Editing